Carolann L. Espy

Carolann L. Espy

Auto-generated profile, based on publicly available information

Carolann L. Espy

Department of Systems Pharmacology and Translational Therapeutics Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Advanced Science
Verified
Journal Article
Open access
NMNicolas Marzolini
Nicolas Marzolini
TBTaylor V. Brysgel
Taylor V. Brysgel
RRRyan J. Rahman
Ryan J. Rahman
EEEno‐Obong Essien
Eno‐Obong Essien
SNSaw Y. Nwe
Saw Y. Nwe
JBJacob S. Brenner
Jacob S. Brenner
DNA‐lipid nanoparticles (DNA‐LNPs) loaded with inhibitors of the cGAS‐STING pathway enable safe and effective delivery of DNA in vivo. Herein, we report the first instances of extrahepatic DNA‐LNP targeting. DNA‐LNPs conjugated to antibodies against PECAM‐1 or VCAM‐1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM‐targeted transgene expression increases over two weeks, resulting in markedly higher lung‐to‐liver expression ratios than our previous PECAM‐targeted mRNA‐LNPs. Off‐target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half‐life. We further improve this expression specificity by replacing full‐length antibodies with Fab fragments. Single‐cell analysis reveals a key mechanism underlying the improvements in organ‐specificity: target organ expression is dominated by long‐lived endothelial cells, while off‐target liver delivery and expression are in non‐endothelial cells with shorter half‐lives. Collectively, these studies demonstrate that targeted DNA‐LNPs achieve high levels of organ‐ and cell‐type‐specific transgene expression and thus provide a therapeutic platform for dozens of endothelial‐centric diseases.

24 March 2026 in Advanced Science
Verified
Journal Article
Open access
CECarolann L. Espy
Carolann L. Espy
JWJichuan Wu
Jichuan Wu
SOSerena Omo‐Lamai
Serena Omo‐Lamai
LWLiuqian Wang
Liuqian Wang
FDFengyi Dong
Fengyi Dong
JBJacob S. Brenner
Jacob S. Brenner
Lipid nanoparticles (LNPs) are widely used for nucleic acid delivery, yet their clinical utility is limited by an acute inflammatory response post‐administration. LNP‐associated inflammation (LAI) manifests as de novo inflammation in select organs (e.g., in the lungs after inhalation) and severely worsens pre‐existing inflammation. NF‐κB is a key transcription factor mediating this inflammation and represents a promising target for LAI mitigation strategies. However, systemic NF‐κB inhibition carries risks of global immunosuppression, highlighting the need for localized inhibition. Here, we screen a panel of direct and indirect small molecule inhibitors of NF‐κB for their ability to reduce LAI without disrupting LNPs’ expression. We identify inhibitors that load efficiently into LNPs, retain anti‐inflammatory activity in vitro and in vivo, and preserve expression of cargo mRNA in target tissues. Our results demonstrate that co‐formulation of NF‐κB inhibitors with cargo nucleic acids enables localized immunomodulation in LNPs, offering a modular strategy to enhance the safety profile of LNPs for therapeutic use in inflammatory or high‐risk patient populations.

12 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NMNicolas Marzolini
Nicolas Marzolini
TBTaylor V. Brysgel
Taylor V. Brysgel
EEEno-Obong Essien
Eno-Obong Essien
RRRyan J. Rahman
Ryan J. Rahman
JWJichuan Wu
Jichuan Wu
JBJacob S. Brenner
Jacob S. Brenner
DNA-lipid nanoparticles (DNA-LNPs) loaded with inhibitors of the cGAS-STING pathway enable safe and effective delivery of DNA in vivo . Herein, we report the first instances of extrahepatic DNA-LNP targeting. DNA-LNPs conjugated to antibodies against PECAM-1 or VCAM-1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM-targeted transgene expression increases over two weeks, resulting in markedly higher lung-to-liver expression ratios than our previous PECAM-targeted mRNA-LNPs. Off-target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half-life. We further improve this expression specificity by replacing full-length antibodies with Fab fragments. Single-cell analysis reveals a key mechanism underlying the improvements in organ-specificity: target organ expression is dominated by long-lived endothelial cells, while off-target liver delivery and expression are in non-endothelial cells with shorter half-lives. Collectively, these studies demonstrate that targeted DNA-LNPs achieve high levels of organ- and cell-type-specific transgene expression and thus provide a therapeutic platform for dozens of endothelial-centric diseases.